Galena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016
July 26, 2016 07:05 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., July 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Announces Closing of Registered Direct Offering
July 13, 2016 16:35 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma to Host Webcast and Conference Call Today
July 08, 2016 07:35 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Announces Pricing of Registered Direct Offering
July 08, 2016 07:05 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Discontinues NeuVax™ (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee Recommendation
June 29, 2016 07:05 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
June 13, 2016 07:05 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Receives Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302
June 10, 2016 14:46 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
June 06, 2016 14:00 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma Receives Fast Track Designation for NeuVax™ (nelipepimut-S) PRESENT Clinical Trial
June 01, 2016 07:05 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum
May 24, 2016 07:05 ET
|
Galena Biopharma, Inc.
SAN RAMON, Calif., May 24, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...